NCT04488510

Brief Summary

A Respiratory infection with the SARS-CoV2 virus is associated with a major risk of viral pneumonia that can lead to respiratory distress requiring resuscitation. In the most severe forms, it may require mechanical ventilation or even lead to an acute respiratory distress syndrome with a particularly poor prognosis. The SARS-CoV2 is a single-stranded RNA virus of positive polarity and belongs to the beta genus of Coronaviruses. SARS-CoV2 is responsible for the third epidemic in less than twenty years secondary to a Coronavirus (SARS-CoV then MERS-CoV) and if the mortality associated with it is lower than that of previous strains, notably MERS-CoV, its spread is considerably big. As a result, the number of patients developing respiratory distress requiring invasive mechanical ventilation is high, with prolonged ventilation duration in these situations

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
22

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Sep 2020

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 23, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 28, 2020

Completed
2 months until next milestone

Study Start

First participant enrolled

September 11, 2020

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 10, 2022

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2023

Completed
Last Updated

March 7, 2023

Status Verified

March 1, 2023

Enrollment Period

2 years

First QC Date

July 23, 2020

Last Update Submit

March 6, 2023

Conditions

Keywords

Pneumonia under mechanical ventilationICUcovid19coronavirusnosocomial pneumoniabacteria

Outcome Measures

Primary Outcomes (1)

  • Research of the bacteria responsible for nosocomial pneumonia

    Establishing a biobank of the bacterial agents responsible for nosocomial pneumonia acquired under mechanical ventilation in order to: better understand the particularities of the bacteria responsible and obtain the "clinical" strains for in vitro studies that will be carried out secondarily.

    6 months

Secondary Outcomes (1)

  • Additional evaluations to the study

    6 months

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patient aged over 18 years, infected by the COVID-19 with a severe form of pneumonia especially the nosocomial pneumonia acquired under mechanical ventilation.

You may qualify if:

  • Patient whose age ≥ 18 years old
  • French-speaking patient
  • Patient whose COVID-19 infection was diagnosed by either a laboratory test, PCR or any other commercial or public health test.
  • Adult acute respiratory distress syndrome according to the Berlin definition
  • Pneumonia acquired under mechanical ventilation defined according to the criteria of international companies

You may not qualify if:

  • Patient/family or proxy opposing participation in the study
  • Patient under guardianship or curatorship
  • Patient deprived of liberty
  • Patient under the safeguard of justice.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Groupe Hospitalier Paris Saint-Joseph

Paris, 75014, France

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

During the inclusion, a 4 ml citrate tube of blood in addition to the usual management assessment and aspiration of tracheal secretions will be performed at D1, D3 and D7. Tracheal aspiration is performed systematically in order to limit patient congestion and the risk of atelectasis.

MeSH Terms

Conditions

COVID-19Pneumonia, Ventilator-AssociatedHealthcare-Associated PneumoniaCoronavirus Infections

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesCross InfectionIatrogenic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • François PHILLIPART, MD

    Fondation Hôpital Saint-Joseph

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 23, 2020

First Posted

July 28, 2020

Study Start

September 11, 2020

Primary Completion

September 10, 2022

Study Completion

April 30, 2023

Last Updated

March 7, 2023

Record last verified: 2023-03

Locations